Stockreport

iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024

iTeos Therapeutics, Inc.  (ITOS) 
PDF WATERTOWN, Mass. and GOSSELIES, Belgium, March 05, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneer [Read more]